Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-09-27 , DOI: 10.1128/aac.01412-21
Deepak Almeida ₁ , Paul J Converse ₁ , Si-Yang Li ₁ , Anna M Upton ₂ , Nader Fotouhi ₂ , Eric L Nuermberger _{1,

3}

Affiliation

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant (MDR/XDR-TB). The newly approved regimen combining ...

中文翻译：

新型二芳基喹啉 TBAJ-876 和贝达喹啉在肺结核小鼠模型中对抗 Rv0678 耐药突变体的疗效比较

Bedaquiline (BDQ, B) 是首个被批准用于治疗结核病 (TB) 的二芳基喹啉。最近的指南推荐将其用于治疗耐多药和广泛耐药 (MDR/XDR-TB)。新批准的方案结合...

更新日期：2021-09-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11